Compare BMM & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMM | SCTX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | Canada | United States |
| Employees | 68 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 545.3M | 536.5M |
| IPO Year | N/A | 2026 |
| Metric | BMM | SCTX |
|---|---|---|
| Price | $5.99 | $31.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 268.0K | 208.5K |
| Earning Date | 05-25-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $17.31 |
| 52 Week High | $8.63 | $39.60 |
| Indicator | BMM | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 57.35 |
| Support Level | $4.73 | $27.20 |
| Resistance Level | $6.53 | $39.60 |
| Average True Range (ATR) | 0.49 | 4.68 |
| MACD | 0.09 | -0.24 |
| Stochastic Oscillator | 68.71 | 37.82 |
Blue Moon Metals Inc is a Canadian exploration stage company focused on the exploration and development of mineral resource properties. The company is advancing its Blue Moon polymetallic deposit which contains zinc, gold, silver, and copper. The projects of the company include the Nussir copper-gold-silver property in Norway (the "Nussir Property"), the Blue Moon zinc-copper-gold-silver property in California, USA (the "Blue Moon Property"), the NSG copper-zinc-gold-silver property in Norway (the "NSG Property") the Springer tungsten-molybdenum project in the Nevada, USA (the "Springer Property") and the Apex germanium-gallium-copper project in Utah, USA (the "APEX Property").
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.